Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Covectra Announces Verification Router Service | Contract Pharma

What are you searching for?

Sign in
Breaking News

Covectra Announces Verification Router Service

Automates management of resalable returns & DSCSA product verification compliance to protect consumers.

By: Contract Pharma

Contract Pharma Staff

Covectra has introduced the Covectra Verification Router Service (VRS), a complete API solution enabling pharmaceutical brands to validate the status of a returned product to ascertain its resell ability and ensure regulatory compliance with the upcoming Drug Supply Chain and Security Act (DSCSA) saleable returns requirement. 
 
Covectra’s new VRS solution automates compliance with standards; offers advanced verification capabilities; and is interoperable with other systems.
 
In November 2020, the FDA enforcement will begin as pharmaceutical distributors of regulated medicines will need to be compliant—or at least on a path to compliance—for the DSCSA saleable returns verification requirement. Implementation of these requirements is intended to enable the U.S. Food and Drug Administration (FDA) to better protect consumers from counterfeit, contaminated, or stolen drugs, and better detect and remove such drugs from the U.S. pharmaceutical supply chain. Wholesalers and distributors will need to verify the unique identifier of returned products before these can be placed into inventory for resale. 
 
Covectra’s new VRS automates DSCSA compliance by managing the acceptance, formatting, and delivery of verification requests and responses for saleable pharmaceutical returns of serialized products in the U.S. It supports secure data exchange between manufacturers and distributors that confirms the authenticity of drug labels, determining if a returned product is in a state which allows it to be resold.
 
“VRS is a key defense mechanism to increase confidence that the U.S. drug supply is authentic, unadulterated, and safe for consumers, said Steve Wood, Covectra’s CEO. “Returned drugs can be fake, substandard and Covectra VRS provides an automated solution to combat this large issue.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics